|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(
e.g.
, puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Transaction Date (MM/DD/YY)
|
3A. Deemed Execution Date, if any (MM/DD/YY)
|
4. Transaction Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
|
6. Date Exercisable and Expiration Date
(MM/DD/YY)
|
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
|
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Series A Preferred Stock
|
(
1
)
|
07/25/2023 |
|
C |
|
|
7,897,999
|
(
1
) |
(
1
) |
Common Stock
|
988,832
|
$
0
|
0
|
I
|
By Versant Venture Capital V, L.P.
(
2
)
|
Series A Preferred Stock
|
(
1
)
|
07/25/2023 |
|
C |
|
|
601,077
|
(
1
) |
(
1
) |
Common Stock
|
75,255
|
$
0
|
0
|
I
|
By Versant Venture Capital V (Canada) LP
(
3
)
|
Series A Preferred Stock
|
(
1
)
|
07/25/2023 |
|
C |
|
|
263,349
|
(
1
) |
(
1
) |
Common Stock
|
32,971
|
$
0
|
0
|
I
|
By Versant Ophthalmic Affiliates Fund I, L.P.
(
4
)
|
Series A Preferred Stock
|
(
1
)
|
07/25/2023 |
|
C |
|
|
237,575
|
(
1
) |
(
1
) |
Common Stock
|
29,744
|
$
0
|
0
|
I
|
By Versant Affiliates Fund V, L.P.
(
5
)
|
Series B-1 Preferred Stock
|
(
1
)
|
07/25/2023 |
|
C |
|
|
3,530,789
|
(
1
) |
(
1
) |
Common Stock
|
442,055
|
$
0
|
0
|
I
|
By Versant Venture Capital V, L.P.
(
2
)
|
Series B-1 Preferred Stock
|
(
1
)
|
07/25/2023 |
|
C |
|
|
268,711
|
(
1
) |
(
1
) |
Common Stock
|
33,642
|
$
0
|
0
|
I
|
By Versant Venture Capital V (Canada) LP
(
3
)
|
Series B-1 Preferred Stock
|
(
1
)
|
07/25/2023 |
|
C |
|
|
117,730
|
(
1
) |
(
1
) |
Common Stock
|
14,739
|
$
0
|
0
|
I
|
By Versant Ophthalmic Affiliates Fund I, L.P.
(
4
)
|
Series B-1 Preferred Stock
|
(
1
)
|
07/25/2023 |
|
C |
|
|
106,208
|
(
1
) |
(
1
) |
Common Stock
|
13,297
|
$
0
|
0
|
I
|
By Versant Affiliates Fund V, L.P.
(
5
)
|
Series B-2 Preferred Stock
|
(
1
)
|
07/25/2023 |
|
C |
|
|
7,650,043
|
(
1
) |
(
1
) |
Common Stock
|
957,787
|
$
0
|
0
|
I
|
By Versant Venture Capital V, L.P.
(
2
)
|
Series B-2 Preferred Stock
|
(
1
)
|
07/25/2023 |
|
C |
|
|
582,206
|
(
1
) |
(
1
) |
Common Stock
|
72,892
|
$
0
|
0
|
I
|
By Versant Venture Capital V (Canada) LP
(
3
)
|
Series B-2 Preferred Stock
|
(
1
)
|
07/25/2023 |
|
C |
|
|
255,081
|
(
1
) |
(
1
) |
Common Stock
|
31,936
|
$
0
|
0
|
I
|
By Versant Ophthalmic Affiliates Fund I, L.P.
(
4
)
|
Series B-2 Preferred Stock
|
(
1
)
|
07/25/2023 |
|
C |
|
|
230,117
|
(
1
) |
(
1
) |
Common Stock
|
28,810
|
$
0
|
0
|
I
|
By Versant Affiliates Fund V, L.P.
(
5
)
|
Series C Preferred Stock
|
(
1
)
|
07/25/2023 |
|
C |
|
|
1,119,729
|
(
1
) |
(
1
) |
Common Stock
|
140,190
|
$
0
|
0
|
I
|
By Versant Venture Capital V, L.P.
(
2
)
|
Series C Preferred Stock
|
(
1
)
|
07/25/2023 |
|
C |
|
|
85,217
|
(
1
) |
(
1
) |
Common Stock
|
10,669
|
$
0
|
0
|
I
|
By Versant Venture Capital V (Canada) LP
(
3
)
|
Series C Preferred Stock
|
(
1
)
|
07/25/2023 |
|
C |
|
|
37,283
|
(
1
) |
(
1
) |
Common Stock
|
4,667
|
$
0
|
0
|
I
|
By Versant Ophthalmic Affiliates Fund I, L.P.
(
4
)
|
Series C Preferred Stock
|
(
1
)
|
07/25/2023 |
|
C |
|
|
33,682
|
(
1
) |
(
1
) |
Common Stock
|
4,216
|
$
0
|
0
|
I
|
By Versant Affiliates Fund V, L.P.
(
5
)
|
Series D Preferred Stock
|
(
1
)
|
07/25/2023 |
|
C |
|
|
2,196,402
|
(
1
) |
(
1
) |
Common Stock
|
274,990
|
$
0
|
0
|
I
|
By Versant Vantage II, L.P.
(
6
)
|
|